Vanderbilt Vaccine Center

April 8, 2020

Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments

Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.

By Bill Snyder
March 23, 2020

Researchers developing potential coronavirus antibody therapies

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.

By Bill Snyder
February 6, 2020

Antibody mixture may help block Ebola virus infection

A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.

By Bill Snyder
February 6, 2020

Carnahan named associate director of Vaccine Center

Robert Carnahan, PhD, associate professor of Pediatrics and Radiology and Radiological Sciences, has been appointed associate director of the Vanderbilt Vaccine Center.

By Bill Snyder
January 23, 2020

Antibody isolated at VUMC found to halt dengue virus

Using part of an antibody isolated at Vanderbilt that “broadly neutralizes” the human dengue virus, biologists at the University of California San Diego and colleagues have disarmed the mosquito that transmits the disabling and potentially deadly tropical infection.

By Bill Snyder
December 12, 2019

VUMC-led team isolates antibody that blocks bird flu

VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans.

By Bill Snyder
December 12, 2019

New tool may speed antibody, vaccine research

By Allison Whitten
September 4, 2019

Partnership to help bring Zika virus therapy to clinic

Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago.
By Bill Snyder
July 9, 2019

Vanderbilt vaccine pioneer James Crowe honored with major science prize

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses.
By Bill Snyder
June 14, 2019

New method tested to block chikungunya infection

Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.
By Bill Snyder
June 6, 2019

VUMC joins international effort to speed vaccine development

VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections.
By Bill Snyder
May 16, 2019

Flu’s “hidden target” may lead to universal vaccine: study

Researchers at Vanderbilt University Medical Center and the Scripps Research Institute have discovered a “hidden target” on the surface of the hypervariable influenza A virus that could lead to better ways to prevent and treat the flu.
By Bill Snyder
April 11, 2019

VUMC-led team ‘sprints’ to develop Zika virus treatment

In January scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis were given an audacious goal to develop — in 90 days — a protective antibody-based treatment that potentially will stop the spread of the Zika virus.
By Bill Snyder
1 2 3 4 5 6 … 9